Document Detail

Evaluation of Levetiracetam as Adjunctive Treatment for Refractory Canine Epilepsy: A Randomized, Placebo-Controlled, Crossover Trial.
MedLine Citation:
PMID:  22295869     Owner:  NLM     Status:  Publisher    
BACKGROUND: There is little evidence-based information available to guide treatment of refractory epilepsy in dogs. The antiepileptic drug levetiracetam (LEV) is administered to dogs, although its safety and efficacy are unknown. OBJECTIVE: To evaluate the safety and efficacy of LEV as adjunctive therapy for refractory epilepsy in dogs. ANIMALS: Thirty-four client-owned dogs with idiopathic epilepsy. METHODS: Randomized, blinded trial involving dogs resistant to phenobarbital and bromide. Dogs received LEV (20 mg/kg PO q8h) or placebo for 16 weeks, and after a 4-week washout were crossed over to the alternate treatment for 16 weeks. Owners kept records on seizure frequency and adverse events. Hemogram, chemistry profile, urinalysis, and serum antiepileptic drug concentrations were evaluated at established intervals. RESULTS: Twenty-two (65%) dogs completed the study. Weekly seizure frequency during the 1st treatment period decreased significantly during LEV administration relative to baseline (1.9 ± 1.9 to 1.1 ± 1.3, P = .015). The reduction in seizures with LEV was not significant when compared to placebo (1.1 ± 1.3 versus 1.5 ± 1.7, P = .310). The most common adverse event was ataxia, with no difference in incidence between LEV and placebo (45 versus 18%, P = .090). No changes in laboratory parameters were identified and owners reported an improved quality of life (QOL) with LEV compared to placebo (QOL score 32.7 ± 4.3 versus 29.4 ± 4.5, P = .028). CONCLUSIONS AND CLINICAL IMPORTANCE: Adjunctive treatment with LEV appears safe in epileptic dogs. Efficacy of LEV over placebo was not demonstrated, although the power of the study was limited. Further evaluation of LEV as treatment for epilepsy in dogs is warranted.
K R Muñana; W B Thomas; K D Inzana; J A Nettifee-Osborne; K J McLucas; N J Olby; C J Mariani; P J Early
Related Documents :
16123089 - Estradiol supplementation modulates neuroendocrine response to m-chlorophenylpiperazine...
9348549 - Neurobiology of tryptophan depletion in depression: effects of m-chlorophenylpiperazine...
24786139 - Community-based prenatal screening for postpartum depression in a south african township.
2440319 - Biogenic amine and metabolite levels in depressed patients with high versus normal hypo...
21954999 - A damage/benefit evaluation of addictive product use.
17987159 - The effect of chiropractic spinal manipulative therapy on salivary cortisol levels.
6219149 - Does lofepramine have fewer side effects than amitriptyline? results of a comparative t...
23429039 - Symptom score for allergic rhinitis.
17417989 - The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-1
Journal Detail:
Title:  Journal of veterinary internal medicine / American College of Veterinary Internal Medicine     Volume:  -     ISSN:  1939-1676     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8708660     Medline TA:  J Vet Intern Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 by the American College of Veterinary Internal Medicine.
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lipase Immobilization on Differently Functionalised Vinyl-Based Amphiphilic Polymers: Influence of P...
Next Document:  The Size 1 ProSeal™ laryngeal mask airway in infants: a randomized, noncrossover study with the Cl...